FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

Pediatric Ethics Subcommittee of the Pediatric Advisory Committee

Agenda:
The Pediatric Ethics Subcommittee of the Pediatric Advisory Committee will meet to discuss a referral by an Institutional Review Board (IRB) of a proposed clinical investigation that involves both an FDA regulated product and research involving children as subjects that may be supported by HHS. The proposed clinical investigation is entitled "Precursor Preference in Surfactant Synthesis of Newborns." Because the proposed clinical investigation would be regulated by FDA, and conducted or supported by HHS; both FDA and the Office for Human Research Protections, HHS, will participate in the meeting.

After presentation of an overview of the IRB referral process, background information on surfactant synthesis, an overview of the protocol and the referring IRB's deliberations on the protocol, and a summary of public comments received concerning whether the protocol should proceed, the subcommittee will discuss the proposed protocol and develop a recommendation regarding whether the protocol should proceed. The subcommittee's recommendation will then be presented to the FDA Pediatric Advisory Committee meeting on June 29, 2005.

Also, a notice announcing a public comment period concerning whether the proposed clinical investigation should proceed has been posted. Information regarding submitting comments during that period is contained in that notice.

Background material and meeting information for the June 28, 2005 meeting will become available no later than one business day before the meeting (simply scroll down to the appropriate committee heading).

Procedure:
Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by June 17, 2005. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 noon. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before June 17, 2005, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Jan Johannessen at least 7 days in advance of the meeting.

Addresses:
Electronic copies of the documents for public review can be viewed on the Pediatric Advisory Committee web page. (simply scroll down to the Pediatric Ethics Subcommittee meeting for 06-28-05) Electronic comments should be submitted to the e-Comment web page of the Division of Dockets Management. Select Docket No. 2005N-0184, entitled "Surfactant IRB Referral" and follow the prompts to submit your statement. Written comments should be submitted to Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Please submit comments by June 17, 2005. Received comments may be viewed on the Dockets web page, or may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Contact Person:
Jan N. Johannessen, Office of the Commissioner (HF-33), Food and Drug Administration, 5600 Fishers Lane (for express delivery, Rm 14C-06), Rockville, MD 20857, 301-827-6687, or by e-mail: jjohannessen@fda.gov.

Advisory Committee Telephone Information Line:
Please call the Information Line for up-to-date information on this meeting, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 8732310001.